✦ LIBER ✦

Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: A randomized trial of the Bristol Lung Cancer Study Group

Book ID: 123462185
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 342 KB
Volume: 6
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(90)90366-T

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Etoposide compared with the combination

Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer

📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Comparison of cyclophosphamide, doxorubi

Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: A Mid-Atlantic Oncology Program study

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Randomised trial of etoposide cyclophosp

Randomised trial of etoposide cyclophosphamide methotrexate and vincristine versus etoposide and vincristine in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Randomized phase II study of cyclophosph

Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma

✍ Shane C. White; Paul Lorigan; Mark R. Middleton; Heather Anderson; Juan Valle; Y 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Cyclophosphamide, epirubicin, and vincri

Cyclophosphamide, epirubicin, and vincristine (CEV) vs cisplatin and etoposide (PE) in the treatment of small cell lung cancer (SCLC): A randomized study

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Efficacy and toxicity of 2 schedules of

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma : A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)

✍ Vincent Ribrag; Christian Gisselbrecht; Corinne Haioun; Gilles Salles; Jean-Bapt 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views